Antibody-targeted radiation cancer therapy

[1]  J. Vose,et al.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2004, Blood.

[2]  J. Jurcic,et al.  Antibody-based treatment of acute myeloid leukaemia , 2004, Expert opinion on biological therapy.

[3]  S. Knox,et al.  Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). , 2003, Seminars in oncology.

[4]  J. Bennett.  Fibrinogen is necessary for platelet function in vivo after all , 2003 .

[5]  D. Oscier,et al.  Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms. , 2003, Blood.

[6]  S. A. Bush,et al.  High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. , 2003, Blood.

[7]  K. Lamborn,et al.  Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  R. Fisher,et al.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. , 2003, Blood.

[9]  M. Brechbiel,et al.  Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation , 2003 .

[10]  P. Johnston,et al.  The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. , 2003, Seminars in oncology.

[11]  M. Brechbiel,et al.  A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  A. Seidman.  Monotherapy options in the management of metastatic breast cancer. , 2003, Seminars in oncology.

[13]  T. Waldmann,et al.  Immunotherapy: past, present and future , 2003, Nature Medicine.

[14]  M. Glennie,et al.  The mechanisms of action of rituximab in the elimination of tumor cells. , 2003, Seminars in oncology.

[15]  D. Milenic.  Monoclonal antibody-based therapy strategies: providing options for the cancer patient. , 2002, Current pharmaceutical design.

[16]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[17]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Chappell,et al.  In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. , 2002, Nuclear medicine and biology.

[19]  I. Bernstein,et al.  The use of radioimmunoconjugates in stem cell transplantation , 2002, Bone Marrow Transplantation.

[20]  Yuni Fang,et al.  Binding to CD20 by Anti-B1 Antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines , 2002, Cancer Immunology, Immunotherapy.

[21]  A. Schubiger,et al.  Copper-67 as a therapeutic nuclide for radioimmunotherapy , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  R. Blumenthal,et al.  Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer , 2002, International journal of cancer.

[23]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[24]  G. Hortobagyi,et al.  Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. , 2001, Seminars in oncology.

[25]  T. Waldmann,et al.  Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Dadachova,et al.  Recent advances in radionuclide therapy. , 2001, Seminars in nuclear medicine.

[28]  J. Schlom,et al.  Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. , 2001, Cancer biotherapy & radiopharmaceuticals.

[29]  C. Meares,et al.  Antibodies with infinite affinity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Brechbiel,et al.  The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. , 2001, Chemical reviews.

[31]  S. Mirzadeh,et al.  In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.

[32]  P. Harari,et al.  Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. , 2001, International journal of radiation oncology, biology, physics.

[33]  S. A. Bush,et al.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. , 2000, Blood.

[34]  J. Hainsworth.  Monoclonal antibody therapy in lymphoid malignancies. , 2000, The oncologist.

[35]  S S Gambhir,et al.  High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Welch,et al.  In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. , 2000, Bioconjugate chemistry.

[37]  R. Meredith,et al.  Clinical radioimmunotherapy. , 2000, Seminars in radiation oncology.

[38]  D. Milenic.  Radioimmunotherapy: designer molecules to potentiate effective therapy. , 2000, Seminars in radiation oncology.

[39]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[40]  J. Vose,et al.  Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Baird.  The pilot study. , 2000, Orthopedic nursing.

[42]  D. Fisher,et al.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. , 2000, Cancer biotherapy & radiopharmaceuticals.

[43]  M. Goris,et al.  Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  S Shen,et al.  A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  M. Cragg,et al.  Signaling antibodies in cancer therapy. , 1999, Current opinion in immunology.

[46]  I. Bernstein,et al.  Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome , 1999 .

[47]  S. Mirzadeh,et al.  In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. , 1999, Cancer biotherapy & radiopharmaceuticals.

[48]  F. D. De Braud,et al.  Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin , 1999, European Journal of Nuclear Medicine.

[49]  J. Poen,et al.  Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. , 1999, Cancer research.

[50]  G. Denardo,et al.  67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[52]  S. Adelstein,et al.  Comparison of strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125. , 1999, Radiation research.

[53]  J. McGahan,et al.  Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Humm,et al.  Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.

[55]  G. Denardo,et al.  Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. , 1998, Anticancer research.

[56]  Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu‐CC49: A phase I/II study , 1997 .

[57]  R. Meredith,et al.  Recent progress in radioimmunotherapy for cancer. , 1997, Oncology.

[58]  D. Goldenberg,et al.  The advantage of residualizing radiolabels for targeting B‐cell lymphomas with a radiolabeled anti‐CD22 monoclonal antibody , 1997, International journal of cancer.

[59]  G. Denardo,et al.  Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. , 1997, Anticancer research.

[60]  J. Schlom,et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. , 1997, Gynecologic oncology.

[61]  M. Zalutsky,et al.  Targeted therapy using alpha emitters. , 1996, Physics in medicine and biology.

[62]  M. Welch,et al.  Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. , 1996, Bioconjugate chemistry.

[63]  R. Levy,et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  S. Larson,et al.  Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. , 1995, Cancer research.

[65]  T. Waldmann,et al.  Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. , 1995, Blood.

[66]  G. Curt,et al.  Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[68]  I. Bernstein,et al.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.

[69]  E. Gautherot,et al.  Bifunctional antibodies for radioimmunotherapy. , 1995, Hybridoma.

[70]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[71]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[72]  T. Waldmann,et al.  Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac , 1994 .

[73]  G. Schieven,et al.  Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. , 1993, Journal of immunology.

[74]  I. Bernstein,et al.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.

[75]  Min Li,et al.  Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. , 1993, Bioconjugate chemistry.

[76]  M. W. Geerlings.  Radionuclides for radioimmunotherapy: criteria for selection. , 1993, The International journal of biological markers.

[77]  Geerlings Mw,et al.  Radionuclides for radioimmunotherapy: criteria for selection , 1993 .

[78]  S. Broder.  Molecular Foundations of Oncology , 1992, Annals of Internal Medicine.

[79]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[80]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[81]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[82]  M. Brechbiel,et al.  212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. , 1988, Journal of the National Cancer Institute.

[83]  J L Humm,et al.  Dosimetric aspects of radiolabeled antibodies for tumor therapy. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[84]  T. Waldmann,et al.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. , 1981, Journal of immunology.

[85]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[86]  R. Laskov,et al.  Studies on a naturally occurring human antibody active against mouse landschutz ascites tumor cells: I. Cytotoxicity assay system and quantitation in normal sera , 1968, International journal of cancer.

[87]  P. Durbin.  Metabolic characteristics within a chemical family. , 1959, Health physics.

[88]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[89]  R. Fisher,et al.  A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911 , 2003 .

[90]  Janet M. Corrigan,et al.  Criteria for Selection , 2003 .

[91]  Y. Junfeng.  Advances in monoclonal antibodies for radioimmunotherapy , 2002 .

[92]  P. Beaumier,et al.  Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[93]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[94]  J. Baselga,et al.  Receptor blockade with monoclonal antibodies as anti-cancer therapy. , 1994, Pharmacology & therapeutics.

[95]  J. Baselga,et al.  Receptor blockade with monoclomal antibodies as anti-cancer therapy , 1994 .

[96]  P. Thorpe,et al.  Targeting the vasculature of solid tumors , 1993 .

[97]  M. Brechbiel,et al.  Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter , 1992 .

[98]  S. Adelstein,et al.  Auger electron emitters: Insights gained from in vitro experiments , 1990, Radiation and environmental biophysics.

[99]  G. Denardo,et al.  Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[100]  P. Ehrlich,et al.  Über einige Verwendungen der Naphtochinonsulfosäure. , 1904 .